This HTML5 document contains 59 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n16http://linked.opendata.cz/resource/drugbank/drug/DB08873/identifier/kegg-drug/
n2http://linked.opendata.cz/resource/drugbank/drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB08873/identifier/drugbank/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/drugbank/drug/DB08873/identifier/national-drug-code-directory/
n6http://linked.opendata.cz/resource/drugbank/dosage/
n5http://www.rxlist.com/
n10http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB08873/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/patent/
n15http://linked.opendata.cz/resource/drugbank/drug/DB08873/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n13http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/atc/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08873
rdf:type
n3:Drug
n3:description
Boceprevir is a direct acting protease inhibitor for the treatment of hepatitis C. It also has two isomers in which the S isomer is more active than the R-isomer. FDA approved on May 13, 2011.
n3:dosage
n6:271B59C4-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Kiser JJ, Flexner C: Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49. doi: 10.1146/annurev-pharmtox-011112-140254. Epub 2012 Nov 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23140245 # Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O'Mara E, Kasserra C, Gupta S, Hughes EA: Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet. 2012 Sep 1;51(9):619-28. doi: 10.2165/11633440-000000000-00000. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22799589 # Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM: Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol. 2012 Apr;26(4):205-10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22506260
n3:group
approved
n3:halfLife
Mean plasma half-life = 3.4 hours
n3:indication
Treatment of chronic hepatitis C genotype 1 in patients that have a compensated liver (as a result of liver diseases like cirrhosis) and are previously untreated or therapy with peginterferon alfa and ribavirin has failed.
owl:sameAs
n10:DB08873
dcterms:title
Boceprevir
adms:identifier
n15:Boceprevir n16:D08876 n18:0085-0314-02 n19:68621 n21:DB08873
n3:mechanismOfAction
Boceprevir inhibits replication of the hepatitis C virus by binding reversibly to nonstructural protein 3/4a (NS3 and NS4A respectively) serine protease. NS4A is a cofactor that works with NS3 for viral replication.
n3:patent
n8:RE43298 n8:7772178 n8:8119602
n3:routeOfElimination
Removed via feces (79%) and urine (9%) which suggest some degree of hepatic excretion.
n3:synonym
SCH 503034 Victrelis
n3:volumeOfDistribution
~722 L
n11:hasAHFSCode
n12:8-18-40
n3:foodInteraction
Food increases the exposure of boceprevir by up to 65%. However, bioavailability is not affected and thus can be taken without regards to meals.
n3:proteinBinding
~75%
n3:synthesisReference
James Lalonde, Tao Li, Jack Liang, Benjamin Mijts, Roger Sheldon, George S.K. Wong, Aleksey Zaks, "Substantially Stereomerically Pure Fused Bicyclic Proline Compounds and Processes for Preparing Boceprevir." U.S. Patent US20120289709, issued November 15, 2012.
foaf:page
n5:victrelis-drug.htm n13:boceprevir.html
n3:IUPAC-Name
n7:271B59C9-363D-11E5-9242-09173F13E4C5
n3:InChI
n7:271B59CF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n7:271B59CE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B59CB-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n7:271B59CC-363D-11E5-9242-09173F13E4C5
n3:SMILES
n7:271B59CD-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n7:271B59C7-363D-11E5-9242-09173F13E4C5
n3:logP
n7:271B59C5-363D-11E5-9242-09173F13E4C5 n7:271B59C8-363D-11E5-9242-09173F13E4C5
n3:logS
n7:271B59C6-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n20:J05AE12
n3:H-Bond-Acceptor-Count
n7:271B59D5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n7:271B59D6-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n7:271B59D0-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n7:271B59D1-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n7:271B59D3-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n7:271B59D2-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n7:271B59D4-363D-11E5-9242-09173F13E4C5
n3:absorption
Food increases exposure of boceprevir by up to 65% relative to fasting state. However, type of food and time of meal does not affect bioavailability of boceprevir and thus can be taken without regards to food. Tmax = 2 hours; Time to steady state, three times a day dosing = 1 day; Cmax, 400 mg single dose, healthy subject = 557 ng/mL; AUC ∞, healthy subject = 2020 ng · h/mL;
n3:affectedOrganism
Hepatitis C virus, RSV and other RNA/DNA viruses
n3:casRegistryNumber
394730-60-0
n3:clearance
Mean total body clearance (Cl/F) = 161 L/h
n3:Bioavailability
n7:271B59DB-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n7:271B59DD-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n7:271B59DE-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n7:271B59DA-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n7:271B59D9-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n7:271B59DC-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n7:271B59CA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n7:271B59D7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n7:271B59D8-363D-11E5-9242-09173F13E4C5